Lung Cancer Update, Issue 1, 2015OVERVIEW OF ACTIVITY LEARNING OBJECTIVES
ACCREDITATION STATEMENT CME credit is no longer available for this issue CREDIT DESIGNATION STATEMENT CME credit is no longer available for this issue HOW TO USE THIS CME ACTIVITY CME credit is no longer available for this issue CONTENT VALIDATION AND DISCLOSURES FACULTY — Dr Adjei has no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Jänne — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Roche Laboratories Inc; Research Funding: Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP. Dr Hanna — Contracted Research: Merck. Dr Schiller — Advisory Committee: AbbVie Inc, Aveo Pharmaceuticals, Biodesix Inc, Eisai Inc, Lilly, Synta Pharmaceuticals Corp; Clinical Studies Grants: Astex Pharmaceuticals, Synta Pharmaceuticals Corp; Consulting Agreements: AbbVie Inc, Aveo Pharmaceuticals, Biodesix Inc, Lilly, Synta Pharmaceuticals Corp; Contracted Research: EMD Serono Inc, Genentech BioOncology. EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc. RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose. This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors. This activity is supported by educational grants from Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Clovis Oncology, Foundation Medicine, Genentech BioOncology, Lilly, Merck and Novartis Pharmaceuticals Corporation. Hardware/Software Requirements: Last review date: October 2015 |